Last month in Denver at AACR, the following were clearly hot topics:

  • miRNA
  • mTOR
  • HDACi
  • Neddylation
  • Cancer stem cells
  • Biomarkers

This month is ASCO at Orlando, my guesses for interesting data are:

  • 1st line lung cancer – Tarceva, Erbitux and Avastin
  • Picoplatin in small-cell lung cancer
  • Afinitor in renal cancer
  • Lapatinib in breast cancer
  • Update on new agents in PTCL and CTCL (sub-set of NHL)

Anyone else have different guesses?

Reblog this post [with Zemanta]